Role of Innate Immune Regulatory Genes, FOXP3 and FOS in Chronic Hepatitis B Infection.

Persistence of hepatitis B virus (HBV) infection leading to chronic infection and its sequalae is responsible for over half a million deaths worldwide. The reason for persistence of chronic hepatitis B (CHB) infection is still not clearly understood. An attempt was made to understand the role of immune regulatory genes in CHB in comparison to spontaneously cleared HBV infection. Relative gene expression of 26 genes involved in innate immunity were studied using Real-Time Polymerase Chain Reaction Array. A total of 679 subjects from three different geographical regions of Northeast India (Assam, Arunachal Pradesh, and Tripura) were included in this case-control study. The cases were subdivided into CHB cases with HBeAg(+)(72), CHB with HBeAg(-)(278), spontaneously cleared controls (88), and healthy controls (228). Overall, 28.3% of the subjects had previous exposure with HBV, while 28.6% had protective antibodies IgG/IgM against HBV. There was a statistically higher number of CHB in men (66.4%) compared to women (33.6%) (p = 0.0001). Proto-oncogene FOS has been found to be moderately upregulated in CHB with HBeAg +ve (2.3-fold) and significantly upregulated (4.1-fold upregulation) in hepatocellular carcinoma. Further, FOXP3 was found to be significantly upregulated (3.0-fold, p = 0.01) in CHB with HBeAg (+) compared to spontaneously cleared HBV infection. In conclusion, CHB with HBeAg positivity was found to have disrupted immune response with upregulation of FOS and FOXP3. Thus, early induction of HBeAg seroconversion with interferon-based therapy or oral nucleos(t)ide analogs along with FOS inhibitors can have important clinical implications in the management of CHB and preventing cirrhosis and HCC.

[1]  Manoj Kumar,et al.  Sequential combination therapies for HBeAg-positive chronic hepatitis B: the search continues , 2021, Hepatology International.

[2]  S. Ahn,et al.  Hepatitis B Virus Cure: Targets and Future Therapies , 2020, International journal of molecular sciences.

[3]  W. Kim,et al.  Prevalence of Chronic Hepatitis B Virus Infection in the United States. , 2020, The American journal of gastroenterology.

[4]  H. Chan,et al.  Unresolved issues of immune tolerance in chronic hepatitis B , 2020, Journal of Gastroenterology.

[5]  Zhiyong Ma,et al.  Interaction between Hepatitis B Virus and Toll-Like Receptors: Current Status and Potential Therapeutic Use for Chronic Hepatitis B , 2018, Vaccines.

[6]  A. M. Ortega-Prieto,et al.  Immune Evasion Strategies during Chronic Hepatitis B and C Virus Infection , 2017, Vaccines.

[7]  R. Lanford,et al.  GS-9620, an oral agonist of Toll-like receptor-7, induces prolonged suppression of hepatitis B virus in chronically infected chimpanzees. , 2013, Gastroenterology.

[8]  B. Ni,et al.  Expression of CD39 on FoxP3+ T regulatory cells correlates with progression of HBV infection , 2012, BMC Immunology.

[9]  P. Hainaut,et al.  Hepatitis B Virus Impairs TLR9 Expression and Function in Plasmacytoid Dendritic Cells , 2011, PloS one.

[10]  Y. Liaw HBeAg seroconversion as an important end point in the treatment of chronic hepatitis B , 2009, Hepatology international.

[11]  Hong Yu,et al.  Patients with chronic hepatitis B infection display deficiency of plasmacytoid dendritic cells with reduced expression of TLR9. , 2009, Microbes and infection.

[12]  A. Pichlmair,et al.  Innate recognition of viruses. , 2007, Immunity.

[13]  S. Yuen,et al.  Natural history and disease progression in Chinese chronic hepatitis B patients in immune‐tolerant phase , 2007, Hepatology.

[14]  Boping Zhou,et al.  Association of CD4+CD25+Foxp3+ regulatory T cells with chronic activity and viral clearance in patients with hepatitis B. , 2006, International immunology.

[15]  Colin W Shepard,et al.  Hepatitis B virus infection: epidemiology and vaccination. , 2006, Epidemiologic reviews.

[16]  F. Chisari,et al.  Immunobiology and pathogenesis of viral hepatitis. , 2006, Annual review of pathology.

[17]  G. Kochs,et al.  The interferon response circuit: Induction and suppression by pathogenic viruses , 2005, Virology.

[18]  Zhenghong Yuan,et al.  Interferon-inducible MyD88 protein inhibits hepatitis B virus replication. , 2004, Virology.

[19]  D. Milich,et al.  Exploring the biological basis of hepatitis B e antigen in hepatitis B virus infection , 2003, Hepatology.

[20]  J. Price,et al.  Is a function of the secreted hepatitis B e antigen to induce immunologic tolerance in utero? , 1990, Proceedings of the National Academy of Sciences of the United States of America.